# Hyperimmune Plasma for Patients With COVID-19

> **NCT04614012** · NA · UNKNOWN · sponsor: **ANNA FALANGA** · enrollment: 100 (estimated)

## Conditions studied

- Covid19

## Interventions

- **OTHER:** treated with hyperimmune plasma

## Key facts

- **NCT ID:** NCT04614012
- **Lead sponsor:** ANNA FALANGA
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-02
- **Primary completion:** 2022-07-02
- **Final completion:** 2022-07-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04614012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04614012, "Hyperimmune Plasma for Patients With COVID-19". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04614012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*